Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Director | July 31, 2026 | August 04, 2026 |
| GT Biopharma, Inc.GTBP · Entity 7878 | Director | September 04, 2025 | September 08, 2025 |
| GridAI Technologies Corp.FWBI · Entity 7534 | Director | January 02, 2024 | January 04, 2024 |
| International Stem Cell CORPISCO.OB · Entity 8432 | Director | June 21, 2018 | June 25, 2018 |
| PaxMedica, Inc.PXMD · Entity 93047 | Director | March 12, 2024 | March 14, 2024 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director | December 12, 2025 | December 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 10,000 · Balance 10,000 F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
GT Biopharma, Inc.
Report date September 04, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2035-08-19 | Direct | 62,500 |
Reported balance
After 2025-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-04 · Grant · Acquired 62,500 · Balance 62,500 F1: The options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The options are fully vested and exercisable.
GridAI Technologies Corp.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,937 |
Reported balance
After 2024-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 19,633 · Balance 19,937 F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
F2: Includes unvested RSUs.
International Stem Cell CORP
Report date June 21, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,431 |
Reported balance
After 2018-06-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-21 · Grant · Acquired 4,328 · Balance 14,431 F1: Common stock granted as part of compensation for non-employee directors, with vesting at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock granted as part of compensation for non-employee directors, with vesting at the time of grant.
PaxMedica, Inc.
Report date March 12, 2024 · Filed March 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,386 |
Reported balance
After 2024-03-12 transaction · row 1
1 source rowRow 1 · 2024-03-12 · Tax withholding · Disposed 992 · Balance 2,386 F1: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.
RELMADA THERAPEUTICS, INC.
Report date December 12, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2035-12-12 | Direct | 164,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 164,000 · Balance 164,000 F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 21:10 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantCommon Stock · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025725 · rdgdoc.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.exercise_date: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.expiration_date: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:07 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001296 · rdgdoc.xml · derivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,928 Underlying: Common Stock · 7,757 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in one annual installment beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F3 · derivative.expiration_date: The restricted stock units vest in one annual installment beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:07 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,196 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-26-001296 · rdgdoc.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,171 Underlying: Common Stock · 12,196 shares Expires 2036-01-11 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 12, 2027. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 14:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Appreciation Rights · Derivative | 164,000 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001213900-25-121967 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2035-12-12 F1 · derivative.exercise_date: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:45 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 62,500 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001641172-25-026891 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2035-08-19 F1 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 23:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-25-059867 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-06-26 F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on September 26, 2025. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:21 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000464 · rdgdoc.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest equally on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 3, 2026. Read SEC document |
| October 22, 2024 Filed Oct 23, 2024 20:27 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-089971 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 21:47 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 13,000 | $2.56 | $33,280.00 |
DisclosureSEC source: 0001213900-24-077794 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| May 24, 2024 Filed May 30, 2024 01:23 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | OtherStock Option (right to buy) · Derivative | 20,976 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047632 · ownership.xml · derivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,522 Underlying: Common Stock · 20,976 shares Expires 2033-12-15 F2 · kind: On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer. Read SEC document |
| May 24, 2024 Filed May 30, 2024 01:23 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 20,976 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-24-047632 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,498 Underlying: Common Stock · 20,976 shares Expires 2033-12-15 F1 · kind: On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 20,976 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:45 UTC | PaxMedica, Inc. PXMD · Entity 93047 | Tax withholdingCommon Stock | 992 | $0.69 | $684.48 |
DisclosureSEC source: 0001104659-24-034545 · tm248854-1_4seq1.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,386 F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:18 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 30,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001437749-24-004363 · rdgdoc.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,555 Underlying: Common Stock · 30,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 13, 2025. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:17 UTC | PaxMedica, Inc. PXMD · Entity 93047 | Tax withholdingCommon Stock | 97 | $0.76 | $73.72 |
DisclosureSEC source: 0001104659-24-008885 · tm244774-2_4seq1.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,378 F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:14 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantCommon Stock | 19,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001440 · tm242126-2_4seq1.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,937 F1 · shares: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 22:26 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 31,522 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001213900-23-097024 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,522 Underlying: Common Stock · 31,522 shares Expires 2033-12-15 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 15, 2024. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:18 UTC | PaxMedica, Inc. PXMD · Entity 93047 | Tax withholdingCommon Stock | 6,536 | $0.29 | $1,869.95 |
DisclosureSEC source: 0001062993-23-019006 · form4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,047 F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 21:44 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 10 | $0.43 | $4.30 |
DisclosureSEC source: 0001104659-23-101684 · tm2326348-1_4seq1.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,098 F1 · balance_after: Includes unvested RSUs. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 00:08 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | SaleCommon Stock | 6,053 | $0.30 | $1,815.90 |
DisclosureSEC source: 0001104659-23-098422 · tm2325486-1_4seq1.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,108 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3001 to $0.3013. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 23:58 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001493152-23-022059 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: 1/12th of the shares vest on the monthly anniversary of May 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:05 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 92,958 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-23-044079 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 92,958 shares Expires 2032-12-16 F1 · date: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 23:10 UTC | PaxMedica, Inc. PXMD · Entity 93047 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-045771 · tm2312952-1_4seq1.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,583 F1 · kind: Consists of 14,000 restricted stock units ("RSUs"). The RSUs are subject to time-based vesting with one-third of the RSUs vesting on February 1, 2024, followed by 8.3325% of the remaining RSUs vesting on a quarterly basis thereafter, subject to the reporting person's continuous service with the Company as of such vesting dates. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 21:10 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001493152-23-006675 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,555 Underlying: Common stock · 25,000 shares Expires 2033-02-19 F1 · date: Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023. F2 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months form the date of grant until fully vested and exercisable on February 20, 2024. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 13:55 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantCommon Stock | 84,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001225 · tm231522-2_4seq1.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,134 F1 · shares: On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 57,042 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001213900-22-081473 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,042 Underlying: Common Stock · 57,042 shares Expires 2032-12-16 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 16, 2023. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 21:26 UTC | PaxMedica, Inc. PXMD · Entity 93047 | GrantCommon Stock | 51,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-105940 · tm2227474d2_4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,583 F1 · kind: Consists of 51,583 restricted stock units ("RSUs"). The RSUs are subject to time-based vesting with one-third of the RSUs vesting on the one-year anniversary of the reporting person's service on the Board of Directors of PaxMedica, Inc. (the "Company"), followed by 8.3325% of the remaining RSUs vesting on a quarterly basis thereafter, subject to the reporting person's continuous service to the Company as of such vesting dates. Read SEC document |
| May 25, 2022 Filed May 26, 2022 22:38 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 91,235 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-22-029832 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 91,235 shares Expires 2031-12-17 F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders. F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionStock Option (right to buy) · Derivative | 19,800 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · derivative · entry 8 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,511 Underlying: Common Stock · 19,800 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 7 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 6 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 5 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 4 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,900 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 3 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 19,800 | $3.24 | $64,152.00 |
DisclosureSEC source: 0001213900-22-018207 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2022 Filed Feb 28, 2022 21:31 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 50,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001493152-22-005612 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,555 Underlying: Common stock · 50,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7, 2023. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 02:07 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantStock option (right to buy) · Derivative | 34,482 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-22-000305 · form4.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,482 Underlying: Common stock, par value $0.0001 per share · 34,482 shares Expires 2032-01-03 F1 · derivative.exercise_date: The stock option vests in equal quarterly installments on each of March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 02:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 58,765 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001213900-21-066819 · ownership.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,765 Underlying: Common Stock · 58,765 shares Expires 2031-12-17 F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022. Read SEC document |
| December 03, 2021 Filed Feb 2, 2023 22:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-007436 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The La Jolla Lenox Trust Disclosed balance after: 10,000 F1 · shares: On December 3, 2021, the Reporting Person transferred 10,000 shares of the Issuer's common stock to a family trust of which the Trustee is someone other than the Reporting Person. The Reporting Person and members of his immediate family are the sole beneficiaries of the trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that The Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 03, 2021 Filed Feb 2, 2023 22:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-007436 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 1,900 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · derivative · entry 5 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,311 Underlying: Common Stock · 1,900 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable F2 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,400 | $29.00 | $40,600.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 4 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,300 | $29.00 | $95,700.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 3 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,900 | $29.00 | $55,100.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 10,000 | $4.60 | $46,000.00 |
DisclosureSEC source: 0001213900-21-049820 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001213900-21-043907 · ownership.xml · derivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,500 Underlying: Common Stock · 10,000 shares Expires 2028-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 10,000 | $4.60 | $46,000.00 |
DisclosureSEC source: 0001213900-21-043907 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,164 | $32.49 | $37,816.38 |
DisclosureSEC source: 0001213900-21-037273 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $32.32 to $32.93 per share, inclusive Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 2,136 | $31.03 | $66,271.96 |
DisclosureSEC source: 0001213900-21-037273 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,854 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $30.66 to $31.60 per share, inclusive. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 2,480 | $33.19 | $82,299.79 |
DisclosureSEC source: 0001213900-21-030571 · ownership.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,950 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $32.85 to $33.42 per share, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.